The use of selective serotonin-reuptake inhibitors (SSRIs) has been associated with an increased risk of bone fracture, raising concerns about their increasingly broader usage. This deleterious effect is poorly understood, and thus strategies to avoid this side effect remain elusive. We show here that fluoxetine (Flx), one of the most-prescribed SSRIs, acts on bone remodeling through two distinct mechanisms. Peripherally, Flx has anti-resorptive properties, directly impairing osteoclast differentiation and function through a serotonin-reuptake-independent mechanism that is dependent on intracellular Ca 2+ levels and the transcription factor Nfatc1. With time, however, Flx also triggers a brain-serotonin-dependent rise in sympathetic output that increases bone resorption sufficiently to counteract its local anti-resorptive effect, thus leading to a net effect of impaired bone formation and bone loss. Accordingly, neutralizing this second mode of action through co-treatment with the -blocker propranolol, while leaving the peripheral effect intact, prevents Flx-induced bone loss in mice. Hence, this study identifies a dual mode of action of SSRIs on bone remodeling and suggests a therapeutic strategy to block the deleterious effect on bone homeostasis from their chronic use. npg
SSRIs, and among them Flx, the active compound in Prozac, are the most widely prescribed antidepressants in western countries. Their therapeutic effect is mediated by a central increase of serotonin signaling in postsynaptic neurons due to an inhibition of serotonin reuptake by the 5-hydroxytryptamine transporter (5HTT), which is expressed by presynaptic neurons 1, 2 . Given their remarkable binding specificity for 5HTT, SSRIs have progressively been favored over less-targeted antidepressants because they decrease the potential for unwanted side effects. They are also increasingly prescribed to treat nonpsychiatric disorders, including preventing hot flashes in menopausal women 3, 4 .
In recent years, however, multiple clinical studies have reported a positive association between the use of SSRIs and a decrease in bone mineral density and/or an increased risk of fractures, raising considerable concern about their broad use [5] [6] [7] . This association between SSRI treatment and bone loss was confirmed in multiple rodent models [8] [9] [10] [11] . Because they bypass a major confounding issue of the clinical analyses, namely that SSRIs are prescribed to depressed individuals and that depression is by itself a possible cause for bone loss 5, 6, 12 , these animal studies have strengthened the notion that treatment with SSRIs could be an independent risk factor for developing osteoporosis. Yet, despite noting a decrease in bone formation [8] [9] [10] these animal studies did not identify the molecular mechanism for this effect on bone or a therapeutic strategy to prevent or treat this side effect. These animal studies also did not explain why chronic administration of SSRIs causes bone loss, as these drugs are designed to increase central serotonin signaling, a pathway known to favor bone mass accrual 13, 14 . To explain this paradox and to define the action of SSRIs on bone remodeling at the molecular level, we analyzed the effect of chronically treating normal, healthy mice for various periods of time. Here we identify a dual mode of action of Flx on bone remodeling that provides a molecular explanation for its observed effects on bone. In particular we show that a short-term (3-week) treatment with Flx results in a local antiresorptive response that increases bone mass but that there is a net loss of bone with longer-term (6-week) use of Flx, which is mediated by a centrally triggered increase in sympathetic activity. On the basis of these findings we then show that co-treating mice with Flx and a β-blocker can prevent this deleterious side effect.
RESULTS

The extent of SSRI use determines their effect on bone mass
Clinical studies reporting bone loss following treatment with SSRIs examined individuals that took these drugs for a relatively long period of time (≥1 year). However, in the rare cases that these analyses were performed after only a few months of treatment, an improved bone density and a decrease in bone resorption parameters have been reported [15] [16] [17] . To test whether the length of treatment correlates with different effects of SSRIs on bone remodeling, we treated wild-type (WT) female mice for 3 or 6 weeks with a dose of Flx that resulted in plasma concentrations similar to the therapeutic levels achieved in humans 18 . In both long bones and vertebrae, the longer-term treatment caused bone loss, whereas mice treated with Flx for the shorter amount of time showed a higher bone volume (measured as the ratio of bone volume to tissue volume; BV/TV) than vehicle (veh)-treated mice (Fig. 1a) .
To understand the cellular basis underlying this time-dependent effect, we performed bone histomorphometry. Mice treated for only 3 weeks with Flx showed lower osteoclast surface (measured as the ratio of osteoclast surface to bone surface; Oc.S/BS), whereas the bone formation rate (measured as bone formation rate to bone surface; BFR/BS) and osteoblast surface (measured as osteoblast surface to bone surface; Ob.S/BS) were not significantly affected as compared to those in veh-treated mice (Fig. 1b,c) . Accordingly, the concentration of deoxypyridinoline cross-links (Dpd), a marker of bone resorption, was lower in Flx-treated than in veh-treated mice, whereas the concentration of osteocalcin (OCN), a marker of bone formation, was not ( Fig. 1d) . In mice that were treated for 6 weeks with Flx, however, histomorphometry and biomarker analysis showed that the osteoclast parameters that were significantly lower after 3 weeks of treatment than those in the veh-treated group were no longer significantly different after 6 weeks of treatment, as compared to those in veh-treated mice (Fig. 1b,d-f ). In contrast, osteoblast parameters, such as bone formation rate and OCN concentration, that were not significantly different after 3 weeks of Flx treatment, relative to those in veh-treated mice, were lower following 6 weeks of treatment with Flx, as compared to those in the veh-treated group (Fig. 1c,d,f,g) .
Flx directly impairs osteoclast differentiation and function
To understand the dual effects of Flx on bone resorption with respect to shorter-term versus longer-term use, we first assessed the ratio of expression of tumor necrosis factor receptor superfamily, member 11b (Tnfrsf11b; also known as osteoprotegerin, OPG) to that of tumor necrosis factor (ligand) superfamily, member 11 (Tnfsf11; also known as RANKL) in long bones, an indicator of a potent osteoblast-driven pathway that regulates osteoclast differentiation and function 19, 20 . Although this ratio was not significantly affected following 3 weeks of treatment, it was lower in mice that were subjected to the longer treatment with Flx than in veh-treated mice ( Fig. 2a) .
To determine whether a direct effect on osteoclasts could be a mechanism by which Flx affects bone homeostasis, we treated primary osteoclast cultures with a dose of Flx similar to the levels observed in plasma and tissues of individuals taking this drug 18 . When mouse primary osteoclast precursors were differentiated in the presence of Flx or other SSRIs, such as paroxetine (Paro) and fluvoxamine (Fluvo), the number of differentiated osteoclasts was significantly lower than in veh-treated cultures (Fig. 2b) ; the veh-and SSRI-treated cultures had similar numbers of mononuclear cells, suggesting that the viability of the osteoclast precursors was not affected (Fig. 2b) . Citalopram (Cita) treatment, however, did not show a significant inhibitory effect on osteoclast differentiation, suggesting the existence of intra-class differences among different SSRIs (Fig. 2b) . The inhibitory effect of Flx on osteoclast differentiation was reversible after its withdrawal from the culture, further ruling out cell death as the basis for this activity (Fig. 2c) . SSRI treatment also directly affected osteoclast function, as primary cultures that were already differentiated and treated for 24 h with Flx, Paro or Fluvo, but not Cita, showed lower tartrate-resistant acid phosphatase (TRAP) activity than veh-treated cells ( Fig. 2d) .
To better understand how Flx influences osteoclast biology, we examined the key processes that mark the differentiation of preosteoclasts into mature, functional osteoclasts: fusion of mononuclear cells into multinucleated osteoclasts, formation of a specific adhesion structure termed the ruffled border and the ability to resorb mineralized bone 19, 20 . Whether it was added to the culture of osteoclast precursors for the duration of the entire differentiation process or only during its final stage, Flx inhibited cell fusion, as indicated by a reduced average number of nuclei in TRAP + multinucleated cells and the reduced expression of dentrocyte-expressed seven-transmembrane protein (Dcstamp) and ATPase, H + transporting, lysosomal V0 subunit D2 (Atp6v0d2), two genes that encode proteins required for this process 19 (Fig. 2e,f) . Adhesion was also affected, as expression of the gene encoding β3-integrin (Itgb3), a key adhesion molecule 19 , was specifically lower, and the supernatant contained more TRAP + cells, in Flx-treated versus veh-treated cultures ( Fig. 2f,g) . These cells were alive, as they could be replated and cultured (Fig. 2g) . In contrast, Flx treatment did not affect formation of the actin ring or expression of the genes encoding proteins required for establishing the ruffled border 21, 22 (Supplementary Fig. 1 ). Finally, we analyzed the effect of Flx exposure on the resorptive capacity of mature osteoclasts. npg Expression of multiple genes that encode proteins involved in this process, such as cathepsin K or subunits of the proton pump, was lower in Flx-treated than in veh-treated cultures, as was pit resorption (Fig. 2h,i) . Taken together these data indicate that Flx treatment directly impairs osteoclast fusion, adhesion and resorptive functions. Notably, the expression of all of the genes controlling these processes and that were found to be affected by Flx treatment in vitro was lower in mice that were treated for 3 weeks with this drug, relative to that in veh-treated mice (Fig. 2j) .
Flx alters calcium signaling in osteoclasts
Given the affinity of SSRIs for 5HTT and its previously reported expression in osteoclasts [23] [24] [25] , we next tested whether 5HTT mediates the direct effect of Flx on osteoclast biology. The ability of Flx npg to inhibit osteoclast differentiation, as assessed by TRAP activity or gene expression, was not impaired in cells derived from mice lacking Slc6a4 (Slc6a4 −/− mice), the gene encoding 5HTT, or Tph1 (Tph1 −/− mice), the gene encoding tryptophan hydroxylase 1, the rate-limiting enzyme for serotonin synthesis ( Fig. 3a and Supplementary Fig. 2a,b) . Moreover, following a 3-week treatment with Flx, Slc6a4-deficient mice showed a modification of their bone histomorphometry profile similar to that in WT mice treated for the same amount of time with Flx, i.e., a bone volume higher than that in veh-treated mice, associated with a lower osteoclast surface (Fig. 3b) . These observations indicate that Flx treatment directly inhibits osteoclast differentiation and function in a 5HTT-independent manner.
To understand how Flx directly affects osteoclast biology differently from its canonical mode of action, we assessed the expression of key factors controlling osteoclast biology 26 . Expression of the transcription-factor-encoding oncogene Fos and that of Nfatc1, a downstream target of Fos (also known as c-FOS), was lower in the presence of Flx than of veh, whereas expression of Cebpa, which is a gene upstream of c-FOS activity in the osteoclast differentiation cascade 27 , was not affected ( Fig. 3c) . Of note, expression of Fos and Nfatc1 was lower in Flx-treated than in veh-treated Slc6a4 −/− cells, again showing that Flx acts directly on osteoclast biology, independently from 5HTT (Fig. 3d) . Expression of Nfatc1 was also significantly lower in the long bones of WT mice that were treated for 3 weeks with Flx than with veh ( Fig. 3e) .
A decrease in Fos expression could be caused by an inhibition of RANKL signaling through the p38 mitogen-activated protein kinase (MAPK) pathway or by an interference with the Ca 2+calmodulin-dependent activation of c-AMP response-element-binding protein (CREB) 28, 29 . Western blot analyses did not detect a change in the phosphorylation of the p38 MAPK (p-p38) after Flx treatment, relative to that after veh treatment ( Fig. 3f) , indicating that direct RANKL signaling is not the main pathway affected. There were, however, significantly lower levels of phosphorylated CREB (p-CREB) in Flx-treated than in veh-treated osteoclasts (Fig. 3f) . npg Fura-2 calcium imaging experiments confirmed that Flx treatment decreases intracellular Ca 2+ levels in multinucleated osteoclasts, whereas it does not have this effect in mononuclear precursors (Fig. 3g) . Moreover treatment with W5, a selective antagonist of Ca 2+calmodulin signaling 30 , abolished the effect of Flx on the expression of osteoclast differentiation markers, as well as on resorptive activity (Fig. 3h,i) . Similarly, reducing Creb1 expression through gene inactivation or blocking CREB transcriptional activity with the KG-501 inhibitor 31 mimicked and blocked the negative effect of Flx on these parameters ( Fig. 3i and Supplementary Fig. 2c ).
Hence, Flx causes its 5HTT-independent inhibitory effect on osteoclast biology by directly impairing a Ca 2+ -calmodulin-CREB-Nfatc1 signaling cascade that is required for their differentiation and function. This effect is reminiscent of the Ca 2+ signaling inhibition observed in Jurkat T lymphocytes treated with Flx 32 . We therefore tested whether mice that were treated with Flx for 3 weeks showed differences in lymphocyte differentiation markers. Indeed, expression of genes encoding CREB, Nfatc1 and Nfatc2, but also that of the master regulator of T helper lymphocyte (T H ) 17 differentiation, ROR-γt (encoded by Rorc), a key component of the osteoimmune cross-talk involved in rheumatoid arthritis 33, 34 , was reduced in the spleens of Flx-treated versus veh-treated mice (Fig. 3j) . These changes in gene expression occurred independently of the serotonin reuptake process, as they could be observed in Slc6a4deficient mice (Fig. 3j) .
Flx inhibits brain serotonin signaling to cause bone loss Although a direct, negative effect of Flx on bone resorption can explain the higher bone mass observed after a 3-week treatment, it cannot explain why a longer-term treatment causes bone loss and a decrease in bone formation. Analysis of primary osteoblast cultures that were treated with Flx ruled out a direct effect on these cells, as Flx did not induce changes in expression of the genes controlling their differentiation or characterizing their function 35, 36 (Supplementary Fig. 3) .
In search for an indirect mechanism that could cause bone loss, we reckoned that the lower bone resorption (relative to that observed after veh treatment) caused by the direct effect of Flx on osteoclasts was no longer apparent after 6 weeks of treatment. This suggested that another, enhancing effect on bone resorption was developing when the treatment was extended. In support of this hypothesis, we found that expression of the gene encoding RANKL, and therefore the Tnfrsf11b/Tnfsf11 ratio, was changed after 6 but not after 3 weeks of treatment with Flx; additionally, Nfatc1 expression was normalized, as compared to that in veh-treated mice, after 6 weeks of treatment ( Figs. 2a and 4a ). An increase in RANKL levels could rescue the inhibitory effect of Flx on the Ca 2+ -calmodulin-Nfatc1 pathway by independently activating the RANK-NF-κB-Nfatc1 cascade 37, 38 . To verify that Flx does not affect this parallel activity of RANKL, RAW264.7 osteoclasts were treated with a low or high dose of RANKL in the presence of Flx or vehicle. In either case, RANKL induced a similar dose-dependent effect: levels of the inhibitor IκBα were lower, Throughout, values are mean ± s.e.m. In all panels, dagger ( † ) represents Flx-treated versus Flx/Prop-treated groups, asterisk (*) represents veh-treated versus Flx-treated groups. † P ≤ 0.05; *P ≤ 0.05; † † P ≤ 0.01; **P ≤ 0.01; † † † † P ≤ 0.0001; ****P ≤ 0.0001; n.s., not significant; by Student's t-tests. (i) Schematic diagram of Flx's mechanism of action on bone remodeling. Flx directly acts on osteoclasts to limit the Ca 2+ -calmodulin-dependent activation of the c-Fos-Nfatc1 cascade, causing a decrease in bone resorption (1), independently of 5HTT. Also, through its inhibition of serotonin reuptake by 5HTT, Flx increases brain serotonin postsynaptic signaling, causing the desensitization of Htr2c (2) . As a result, sympathetic output increases, bone resorption increases and bone formation decreases. After a short exposure to Flx, the direct effect (1) is predominant, causing an increase in bone mass by decreasing bone resorption. Following a longer treatment, direct (1) and central (2) effects counteract each other in terms of bone resorption, while bone formation decreases, causing bone loss. The deleterious central effect of fluoxetine (2) on bone remodeling can be prevented by a co-treatment with propranolol, which blocks the increase in Adrb2 (β2-adrenergic receptor) signaling in osteoblasts caused by the higher sympathetic tone. and nuclear levels of the transcription factor NF-κB p65 were higher, than in control cells ( Fig. 4b and Supplementary Fig. 4 ).
An increase in RANKL-mediated, OPG-expression-independent bone resorption associated with a decrease in bone formation is a hallmark of the effect of sympathetic signaling in osteoblasts 39, 40 . We therefore tested whether a longer-term treatment with Flx increased sympathetic output. Indeed, the concentrations of epinephrine (E) and norepinephrine (NE), the two main effectors of the sympathetic nervous system (SNS), in urine were significantly higher after 6 weeks but not after 3 weeks of treatment with Flx than in veh-treated mice (Fig. 4c) . Similarly, expression of Ucp1 in brown fat, a marker of SNS activity, was higher only in mice treated with Flx for 6 weeks, as compared to Ucp1 levels after 3 weeks of Flx treatment or after veh treatment (Fig. 4d) .
We then explored how Flx could affect sympathetic output. Both the hypothalamic expression of butyrylcholinesterase (Bche), a gene upregulated in the absence of brain serotonin signaling 14 , and the concentration of NE in brain stem extracts were higher in Flx-treated than in veh-treated mice (Fig. 4e) . These observations suggested that Flx could impair signaling of the central serotonin-Htr2c serotonin receptor pathway that is known to specifically influence bone remodeling 13, 14 . Indeed, hypothalamic extracts from mice treated for 6 weeks with Flx showed significantly lower levels of phosphorylated CREB (p-CREB), a downstream mediator of serotonin signaling through Htr2c 14 , as compared to mice treated with veh ( Fig. 4f) . This effect was even more pronounced after comparisons to mice that were treated for only 3 weeks with Flx, as these showed the increase in p-CREB hypothalamic levels that Flx is expected to induce after increasing serotonin signaling (Fig. 4f) . A similar biphasic effect could also be observed after Neuro2A neuroblastoma cells that robustly express Htr2c were treated with increasing amount of serotonin ( Fig. 4g and Supplementary Fig. 5) . These data suggest that by progressively increasing serotonin signaling in the brain, Flx can induce Htr2c desensitization, a classic feature of G-proteincoupled receptor (GPCR) signaling 41 . Of note, western blot analyses also showed that levels of Htr2c in hypothalamic extracts became gradually lower after 3 and 6 weeks of Flx treatment than in vehtreated controls (Fig. 4f) . These data support the notion that, with time, Flx decreases serotonin signaling in the hypothalamus.
To confirm genetically that the central effect of Flx is serotonin dependent, we treated mice lacking Tph2, the gene encoding the enzyme required for brain serotonin synthesis, with Flx or vehicle for 6 weeks. In contrast to the effect observed in WT mice, Flx failed to modify sympathetic output or the Tnfrsf11b/Tnfsf11 ratio in Tph2 −/− mice (Fig. 4h) . As a result, treatment of these mutant mice with Flx did not show reduced bone-formation parameters, and these mice did not lose bone, as compared to veh-treated Tph2 −/− mice (Fig. 4i) . Instead, their bone volume was improved due to a lower osteoclast surface (Fig. 4i) . This phenotype, which mimics the one observed in WT mice treated with Flx for 3 weeks, indicates that in absence of a central effect, Flx anti-resorptive peripheral activity persists after 6 weeks of treatment. A similar improvement in bone volume was observed in Slc6a4 −/− mice that were treated for 6 weeks with Flx, as compared to their veh-treated counterparts (Fig. 4j) . Thus, Flx does not use another unexpected and serotonin-independent mechanism than its known action on brain 5HTT to induce bone loss.
Given that most of the clinical data on the effect of SSRIs on bone health were acquired in women, all of the previous experiments were performed in female mice. To test whether Flx exerts the same action in both genders, we next treated groups of male mice with Flx. As in the female mice, bone loss could be observed in both the vertebrae and the long bones after 6 weeks of Flx treatment, as compared to that observed after vehicle treatment (Fig. 5a) . This effect was due to reduced bone formation, as indicated by a sharp drop in the serum OCN concentration (Fig. 5b) , whereas the concentration of the resorption marker Dpd was not statistically different between the Flx-and veh-treated groups, despite a markedly lowered Tnfrsf11b/ Tnfsf11 ratio (Fig. 5c,d) . As in the female mice, this phenotype was associated with a trend for higher SNS output, although this did not reach statistical significance for changes in E and NE concentrations (Fig. 5e,f) . Likewise, Flx treatment triggered similar inhibitory responses with respect to gene expression and function, as compared to veh treatment, in primary osteoclasts derived from male mice as it did from those derived from female mice ( Fig. 5g-i) .
Co-treatment with propranolol prevents Flx-induced bone loss
If the bone loss induced by longer-term Flx use results from an increase in SNS output, then decreasing SNS signaling in bone cells should prevent this side effect. To test this hypothesis we analyzed WT mice co-treated for 6 weeks with Flx and a low, 0.5 mg/d, dose of propranolol (Prop), which does not significantly affect bone mass accrual by itself ( Fig. 6a-d) . Compared to mice treated with Flx alone, mice treated with both drugs did not lose bone and showed normal bone-formation parameters and lower bone-resorption parameters, as assessed by histomorphometry of vertebrae and serum concentration of biomarkers ( Fig. 6a-c) . Similar results were obtained on tibiae that were analyzed by micro-computed tomography (µ-CT) (Fig. 6d) . In agreement with the role of sympathetic signaling in osteoblasts 39, 40 , the Tnfrsf11b/Tnfsf11 ratio, and more specifically the expression of the gene encoding RANKL, was normalized in mice that were co-treated with Flx and propranolol, as compared to those treated with Flx alone, although their sympathetic tone was similarly high when compared to veh-or Prop-treated mice ( Fig. 6e-g) . Notably, in a marble-burying test we used throughout the study as a functional readout of the effect of Flx on behavior (Supplementary Fig. 6) , the co-treatment with a low dose of propranolol did not alter this aspect of Flx activity (Fig. 6h) , suggesting that Flx's central action on this behavior was not affected.
DISCUSSION
This study shows that Flx affects bone mass accrual in mice through two distinct mechanisms (Fig. 6i) . In particular, Flx can interfere directly with Ca 2+ -calmodulin signaling in osteoclasts to decrease CREB phosphorylation, as well as Fos and Nfatc1 expression, thereby impairing the maturation and activity of these cells. This mechanism of action is consistent with the reduced bone resorption observed in mice treated with Flx for 3 weeks, as compared to that in the vehtreated group, and is independent of the 5HTT transporter. After a longer treatment (6 weeks), however, this direct inhibitory effect on osteoclasts is counteracted and a decrease in bone formation leads to bone loss. This second effect is associated with decreased serotonin signaling in the hypothalamus and increased SNS output. Accordingly, normalization of sympathetic output with a low dose of propranolol can prevent Flx-induced bone loss.
It should be noted that the two independent effects exerted by Flx on bone remodeling are not binary effects, and the 3-and 6-week time points are arbitrary points in what is a continuum of bone remodeling. Indeed, at the 3-week time point bone parameters already appear to be trending down, although not significantly, in the Flx-treated versus veh-treated mice. Similarly, osteoclast surface still trails down after 6 weeks of treatment.
npg Brain serotonin, which signals through an Htr2c-CREB cascade, positively regulates bone mass accrual by inhibiting sympathetic output 13, 14 . Thus, how can Flx treatment mimic the effect of a decrease in brain serotonin signaling on bone remodeling, whereas its canonical activity on 5HTT should increase this activity? In agreement with previous studies showing that high concentrations of serotonin can desensitize Htr2c [42] [43] [44] , our data show lower hypothalamic levels of phosphorylated CREB, its downstream mediator, after 6 weeks of treatment with Flx, as compared to that with veh treatment. In addition, mice that were treated with Flx for 3 and 6 weeks had progressively lower levels of hypothalamic Htr2c compared to veh-treated mice. Thus, with time, Flx decreases serotonin signaling in Htr2c neurons and thereby causes a negative effect on bone remodeling similar to that seen with an absence of brain serotonin 13, 14 . This central-SNS-mediated detrimental activity on bone remodeling seems to be delayed as compared to the direct, anti-resorptive action of Flx. This difference in timing could stem from the fact that more time could be needed for this drug to cause an increase in intersynaptic brain serotonin levels that would be sufficient to desensitize the Htr2c receptor and decrease its expression than to reach osteoclasts peripherally and directly disrupt their function.
An unexpected finding of our study is the fact that Flx can function directly on osteoclasts through a pathway that is different from its canonical mode of action. Although cells from the osteoclast lineage express 5HTT and the gene encoding Tph1, osteoclasts derived from mice lacking expression of these proteins respond to Flx similarly to WT cells 23, 24, 45 . Thus, at least in mice, Flx acts on these cells independently of the serotonin-5HTT system. Instead, this drug directly impairs Ca 2+ -calmodulin signaling. This ability of Flx to interfere with intracellular Ca 2+ homeostasis has been observed in other cell types 32, 46, 47 . Accordingly, Flx can impair extracellular Ca 2+ influx by blocking various voltage-gated and ligand-gated ion channels [47] [48] [49] . More recently, Flx was also found to inhibit inositol 1,4,5-trisphosphate (IP 3 )-and ryanodine-receptor-mediated Ca 2+ release from intracellular stores in lymphocytes, an effect that could explain the poorly understood immunomodulatory activity of SSRIs 32, [50] [51] [52] [53] . Additional studies will be needed to determine which of these mechanisms occurs in osteoclasts. Furthermore, through a simultaneous inhibition of osteoclast function and a decrease in T H 17 lymphocyte activation 34, 50, 54 , this mode of action could also explain the beneficial effect of SSRIs on multiple outcomes of osteoarthritis in mice and humans [55] [56] [57] . Again, additional studies are required to test this possibility.
More generally, considering that our study was performed using mouse models, one cannot exclude that differences could exist between the mechanisms we describe in mice and those in humans taking SSRIs. Yet, the dual effect of Flx on bone remodeling that we observe in our mouse models is consistent with data reported in the clinical literature. For instance, most clinical studies analyzed long-term SSRI users and found a negative effect on bone health 5, 6, 9, 11 , consistent with the central effect of Flx on the sympathetic tone that we identified. In line with this notion, Flx increases the plasma concentration of epinephrine and norepinephrine in individuals 58 , suggesting that, as in mice, decreasing sympathetic signaling in osteoblasts through the use of a β2-blocker could prevent bone loss in long-term users of SSRIs. Similarly, in agreement with the antiresorptive activity of Flx, individuals evaluated shortly after taking SSRIs show higher calcaneal bone-mineral density (BMD) T-score and lower serum concentration of the resorption biomarker carboxy-terminal collagen cross-links (CTx) 15, 16 . Finally, we show that citalopram does not inhibit mouse osteoclast differentiation, and others have reported that escitalopram, its S-enantiomer, did not affect bone resorption in women who were not depressed and who were treated for a short time with this drug 59 . These observations illustrate that all SSRIs may not have a similar effect on bone remodeling and that in animal studies, as in clinical reports, more attention should be given to potential intraclass differences.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Mice and in vivo treatments. We purchased male and female C57BL6/J and Slc6a4 −/− mice from the Jackson Laboratories (Bar Harbor, Maine). Generation of Tph2 −/− mice was reported previously 13 . We generated Tph1 −/− mice by crossing Tph1 fl/fl mice 60 and EIIA-Cre mice, in which Cre recombinase is expressed under the adenovirus EIIA promoter. All mice were analyzed on the C57BL6/J background. We added fluoxetine hydrochloride USP (Flx; 20 mg per kg body weight per day (mg/kg/d); Voigt Global Distribution Inc., Lawrence, Kansas) and propranolol (Prop; 0.5 mg/d; Sigma, St. Louis, Missouri) aseptically to the drinking water of virgin female or male mice. We treated mice for either 3 weeks or 6 weeks, as indicated in each specific case, replacing bottles every other day. All mice were analyzed between the ages of 17 and 20 weeks. Any mouse displaying immobility, huddled posture, inability to eat or drink, ruffled fur, self-mutilation, vocalization, wound dehiscence or signs of hypothermia was excluded from the study. In all experiments, animals were randomly assigned to the veh-or Flx-treated groups. For all assays, investigators were blinded to the type of treatment. The Columbia University Institutional Animal Care and Use Committee (IACUC) approved all of the procedures.
Measurement of biomarkers.
We collected blood samples through cardiac puncture under Avertin anesthesia, using Multivette 600 tubes from Sarstedt (Numbrecht, Germany), and centrifugation at 13,000g for 10min at 4 °C. We measured the concentration of OCN with the Ocn IRMA kit (Immutopics, San Clemente, California). We collected urine samples in the mornings for at least 3 d within the week prior to euthanization and measured the concentrations of Dpd with the Dpd EIA kit (Quidel, San Diego, California) and of E and NE with the Bi-CAT ELISA kit (Alpco, Salem, New Hampshire). We reported the urine concentrations of Dpd, E and NE relative to concentrations of creatinine in the urine, as quantified with the Creatinine EIA kit (Quidel). We measured epinephrine content in the brain stem by HPLC, with a modified method described previously 61 . Briefly, dissected brain samples were homogenized in 0.4 M perchloric acid with an Ultra Cell Disruptor (Microson). The homogenate was centrifuged for 5 min at 14,000g in a cold room, and 50-µl of a typically 4× diluted aliquot of the supernatant was injected over the HPLC system, which was equipped with a Varian Microsorb 100-5 C18 reverse-phase column (DYNAMAX 150 × 4.6 mm). The mobile phase contained 0.75 mM sodium phosphate (pH 3.1), 1.4 mM 1-octanesulfonic acid, 10 µM sodium EDTA and 8% acetonitrile, and the flow rate was maintained at 0.8 ml/min. Values were calculated based on peak area and were compared to those of standard solutions. The inter-and intra-assay coefficients of variation of the assay were each <5%. The sensitivity of the assay was <0.5 pmol/injection. Cell culture, in vitro treatments and imaging. We obtained mouse primary osteoclast precursors (monocytes) by culturing bone marrow cells with macrophage colony-stimulating factor (M-CSF)-containing L-929 cell(ATCC, Massanas, Virginia) supernatant (10%) for 5-6 d in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS. We then differentiated osteoclast precursors with 30 ng/ml of RANKL (R&D Systems Inc., Minneapolis, Minnesota) and 10 ng/ml of M-CSF (R&D Systems Inc.) in alpha minimal essential medium (alpha-MEM) with 10% FBS for 6 d. We cultured RAW264.7 cells (ATCC) in DMEM with 10% FBS and differentiated them with 30 ng/ml RANKL (R&D Systems Inc.) in alpha MEM with 10% FBS for 3 d before Flx treatment. Medium was replaced every 48 h. We isolated mouse primary osteoblasts from 3-d-old pups and cultured them with alpha MEM with 10% FBS for 2 d, as previously described 62 . Osteoblasts were differentiated in alpha MEM with 10% FBS, 100 µg/ml l-ascorbic acid and 5 mM β-glycerophosphate for 6 d in the presence of veh or Flx (3 µM). We cultured Neuro2A cells (ATCC) in DMEM with 10% FBS and starved them in 0.5% FBS for 16−18 h before serotonin treatment. Creb1 −/− osteoclasts were generated by infecting Creb1 fl/fl cells with either empty vector or Cre-expressing adenovirus (1:800 multiplicity of infection (MOI)) (University of Iowa). We did not test the cultures of primary cells or cell lines for mycoplasma infection. Primary cell cultures were authenticated through gene expression analysis of specific markers.
We dissolved fluoxetine (Voigt Global Distribution Inc., Lawrence, Kansas), paroxetine (Abcam, Cambridge, Massachusetts), fluvoxamine (Abcam) and citalopram (Abcam) at 10 mM in 0.9% NaCl and added them to the medium, to the final concentration of 3 µM, for 6 d (end point) or only during the final 24 h of culture. In the 6-d treatment, medium was replaced every 48 h. We dissolved W-5 (Santa Cruz) at 10 mM in water and added it to the medium to the final concentration of 50 µM. We dissolved KG-501 (Sigma) at 10 mM in DMSO and added it to the medium to the final concentration of 10 µM. For detached live-cell analysis, we treated cultures of mature osteoclasts for 24 h with fluoxetine or vehicle; then we collected and centrifuged the medium. We subjected the pellets to a TRAP assay or re-seeded them in new plates and cultured the cells in osteoclast differentiation medium until we stained the plates with TRAP (see below). For counting the number of nuclei/osteoclast, we fixed primary osteoclasts in 4% formaldehyde and stained for both actin, with a 1:100 dilution of Alexa-Fluor-548-conjugated phalloidin (Life Technologies, A12380), and nuclei, with DAPI at 0.2 µg/ml (Life Technologies).
We imaged cultures under a bright field (for TRAP staining) or a fluorescent light (for actin) with a Leica DM400B (Wetzlar, Germany). We used ImageJ software (National Institutes of Health) to quantify the number of cells and nuclei for each osteoclast.
TRAP and pit-resorption assays. For TRAP staining, we fixed primary osteoclast cultures in 10% formalin, washed the cells and incubated them with TRAP staining reagent (0.5 mg/ml naphthol AS-MX phosphate (Sigma), 0.4 mg/ml Fast Red violet (Sigma) in acetate-tartrate buffer (25 mM sodium acetate and 20 mM sodium tartrate, pH 5)) for 30 min at room temperature (RT). For TRAP quantification in supernatant, we incubated 50 µl of culture medium for 1 h at 37 °C with 50 µl of 10 mM p-nitrophenyl phosphate substrate (pNPP; Sigma) in TRAP assay buffer (200 mM sodium chloride, 200 mM sodium citrate and 80 mM of sodium l-(+)-tartrate, pH 5). We stopped the reaction by adding 50 µl of 3 M NaOH and performed colorimetry at 405 nm versus a reference at 490 nm, using a microplate reader (Bio-Rad 680, Hercules, California). We calculated TRAP activity as (Abs 405nm × vol (ml))/(ε × time (min)), where ε is the molar extinction coefficient (17.8 mM −1 cm −1 for pNPP). We processed and read technical duplicates of each sample. We performed pit-resorption assays using Osteo Assay Stripwell Plates (Corning, New York, New York), following the manufacturer's protocol.
Gene expression, protein analyses and immunocytochemistry. We purified RNA from cells in culture and tissues using TRIzol (Invitrogen, Grand Island, New York), following the manufacturer's protocol. We flushed the long bones for bone marrow before RNA purification. We performed real-time PCR (qPCR) with the Taq SYBR Green Power PCR Master Mix (Invitrogen) on a CFX Connect instrument (Bio-Rad, Hercules, California); amplification of glyceraldehyde-3-phosphate dehydrogenase (Gapdh) or hypoxanthine guanine phosphoribosyl transferase (Hprt; in case of brain samples) was used as an internal reference for each sample. Verification of amplicon specificity was tested through a BLAST search, and the size of amplicons was verified by gel electrophoresis. Dissociation-curve analysis was performed for every experiment. Sequences of the primers used for each gene are available upon request.
We subjected protein extracts from cells or tissue to western blotting, using antibodies to the following proteins: phospho-CREB in Figure 3f (1:1,000, Cell Signaling, Danvers, Massachusetts, 9198), phospho-CREB in all other figures (1:1,000, Merck Millipore, Billerica, Massachusetts, 06-519), CREB (1:1,000, Cell Signaling, 9104), phospho-p38 MAPK (1:1,000, Cell Signaling, 9211), p38 MAPK (Cell Signaling, 9212), IκBα (1:5,000, Cell Signaling, 4814), Gapdh (1:5,000, Cell Signaling, 5174) and Htr2c (1:500, Santa Cruz sc-17797). We visualized immunocomplexes with a horseradish peroxidase (HRP)-conjugated anti-rabbit-or anti-mouse-IgG antibody (1:2,000), followed by incubation with ECL western blot reagent (GE Healthcare, Indianapolis, Indiana). Imaged blots were quantified using the ImageJ software. For all antibodies, validation is provided in the manufacturer's website.
For NF-κB p65 localization by immunocytochemistry, we grew RAW264.7 cells until differentiation and depleted them of RANKL for 1 h. Subsequently, we incubated them for 30 min with the indicated amounts of RANKL, and with vehicle or Flx as indicated. Then we fixed them in 4% formaldehyde, incubated them in PBS with 0.5% Triton X-100 for permeabilization and then treated them with PBS containing 10% FBS to block nonspecific binding. We incubated them overnight at 4 °C with an antibody to NF-κB p65 (1:400, Cell Signaling, 8242).
